These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 2387656)

  • 1. Current French system of post-marketing drug surveillance.
    Albengres E; Gauthier F; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1990 Jul; 28(7):312-4. PubMed ID: 2387656
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Features of the French postmarketing drug surveillance system. Application to cutaneous effects of nonsteroidal antiinflammatory drugs.
    Albengres E
    J Rheumatol Suppl; 1988 Oct; 17():20-3. PubMed ID: 3204616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Organization and results of drug vigilance in France].
    Bégaud B; Chaslerie A; Haramburu F
    Rev Epidemiol Sante Publique; 1994; 42(5):416-23. PubMed ID: 7973001
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [French system of drug surveillance].
    Imbs JL; Castot A; Begaud B; Larousse C; Blayac JP; Alexandre JM
    Bull Acad Natl Med; 1998; 182(7):1383-91; discussion 1392-3. PubMed ID: 9916332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. How to anticipate the assessment of the public health benefit of new medicines?
    Massol J; Puech A; Boissel JP;
    Therapie; 2007; 62(5):427-35. PubMed ID: 18206104
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Computerized detection of new adverse effects in drug surveillance. A proposal for the periodic use of the French data bank].
    Pham E; Ventre JJ; Saddier P; Descotes J; Evreux JC
    Therapie; 1988 May; 43(3):235-7. PubMed ID: 3420571
    [No Abstract]   [Full Text] [Related]  

  • 8. [Imputation of the unexpected or toxic effects of drugs. Actualization of the method used in France].
    Bégaud B; Evreux JC; Jouglard J; Lagier G
    Therapie; 1985; 40(2):111-8. PubMed ID: 4002188
    [No Abstract]   [Full Text] [Related]  

  • 9. [Drug by drug imputation of adverse effects in drug monitoring. Attempted comparison of different methods].
    Lagier G; Vincens M; Lefebure B; Frelon JH
    Therapie; 1983; 38(3):295-302. PubMed ID: 6612666
    [No Abstract]   [Full Text] [Related]  

  • 10. [Drug surveillance and adverse reactions to drugs. The literature and importance of historical data].
    Mariani L; Minora T; Ventresca GP
    Clin Ter; 1996 Dec; 147(12):653-72. PubMed ID: 9296925
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Mandatory report of adverse effects of drugs: has the order modified the spontaneous notification?].
    Haramburu F; Pere JC; Begaud B; Albin H
    Therapie; 1988; 43(6):493-6. PubMed ID: 3227516
    [No Abstract]   [Full Text] [Related]  

  • 12. Advantages of adverse-effect reporting by patients.
    Prescrire Int; 2011 Mar; 20(114):70. PubMed ID: 21648228
    [No Abstract]   [Full Text] [Related]  

  • 13. [Is imputation in drug surveillance reliable?].
    Girard M
    Therapie; 1984; 39(3):291-6. PubMed ID: 6463954
    [No Abstract]   [Full Text] [Related]  

  • 14. Emergency department visits for outpatient adverse drug events: demonstration for a national surveillance system.
    Budnitz DS; Pollock DA; Mendelsohn AB; Weidenbach KN; McDonald AK; Annest JL
    Ann Emerg Med; 2005 Feb; 45(2):197-206. PubMed ID: 15671977
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Statewide test of a new postmarketing drug surveillance system.
    Fisher S; Bryant SG; Solovitz BL; Kluge RM
    Tex Med; 1987 Aug; 83(8):59-62. PubMed ID: 3660262
    [No Abstract]   [Full Text] [Related]  

  • 16. [Official systems of pharmacovigilance in France and in Spain. Comparison of spontaneous reporting in two regional centers: Pays Basque and Bordeaux].
    Aguirre C; Haramburu F
    Therapie; 1995; 50(6):563-9. PubMed ID: 8745957
    [TBL] [Abstract][Full Text] [Related]  

  • 17. An underrecognized challenge in evaluating postmarketing drug safety.
    Roden DM
    Circulation; 2005 Jan; 111(3):246-8. PubMed ID: 15668350
    [No Abstract]   [Full Text] [Related]  

  • 18. How do pharmaceutical companies handle consumer adverse drug reaction reports? An overview based on a survey of French drug safety managers and officers.
    Fleuranceau-Morel P
    Pharmacoepidemiol Drug Saf; 2002; 11(1):37-44. PubMed ID: 11998550
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Drug monitoring].
    Royer RJ
    Bull Soc Ophtalmol Fr; 1985 Nov; Spec No():11-30. PubMed ID: 4064240
    [No Abstract]   [Full Text] [Related]  

  • 20. The US drug safety system: role of the pharmaceutical industry.
    Gibson BR; Suh R; Tilson H
    Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.